达沙替尼联合强化化疗治疗新诊断儿童费城染色体阳性急性淋巴细胞白血病(CA180-372/COG AALL1122):一项单臂、多中心、2期试验
该单臂多中心2期研究纳入109例新诊断Ph阳性急性淋巴细胞白血病患儿,106例接受达沙替尼60 mg/m2每日一次联合EsPhALL化疗。3年无事件生存率65.5%,优于单纯化疗(49.2%,p=0.032),非劣于伊马替尼联合化疗(59.1%),但未优于后者(p=0.27)。
要点
- 达沙替尼联合EsPhALL化疗在儿童Ph阳性ALL中安全且有活性。
- 3年无事件生存率65.5%,优于历史单纯化疗对照49.2%。
- 3年无事件生存率非劣于但未优于伊马替尼联合化疗的59.1%。
核心结论
- 达沙替尼联合EsPhALL化疗在儿童Ph阳性急性淋巴细胞白血病中安全且有活性。
- 3年无事件生存率与既往Ph阳性急性淋巴细胞白血病试验相似,尽管首次完全缓解期造血干细胞移植使用有限。
研究设计与样本
- CA180-372/COG AALL1122为儿童肿瘤协作组(COG)与欧洲儿童Ph阳性ALL协作组(EsPhALL)联合开展的开放标签、单臂、2期研究。
- 纳入年龄>1岁至<18岁、新诊断Ph阳性急性淋巴细胞白血病且体能状态至少60%的患者,接受EsPhALL化疗联合达沙替尼60 mg/m2口服每日一次,自诱导第15天开始。
- 诱导1B后微小残留病≥0.05%或三个巩固块后微小残留病阳性的患者归为高危,分配至首次完全缓解期接受造血干细胞移植;其余为标准风险,接受化疗联合达沙替尼2年。
- 主要终点为达沙替尼联合化疗与外部历史对照的3年无事件生存率比较;2012年3月13日至2014年5月27日共入组109例患者,来自69个中心(包括美国、加拿大、澳大利亚的51个COG中心和意大利、英国的18个EsPhALL中心)。
- 3例不符合条件未接受达沙替尼,106例接受治疗并纳入安全性和疗效分析(女性49例[46%],男性57例[54%])。
主要发现
- 全部106例治疗患者均达到完全缓解;87例(82%)归为标准风险,19例(18%)符合造血干细胞移植标准归为高危,但仅15例(14%)在首次完全缓解期接受了造血干细胞移植。
- 达沙替尼联合化疗的3年无事件生存率为65.5%(90% Clopper-Pearson CI 57.7至73.7),优于单纯化疗的49.2%(38.0至60.4),p=0.032。
- 达沙替尼联合化疗的3年无事件生存率非劣于伊马替尼联合化疗的59.1%(51.8至66.2),治疗差异90% CI为-3.3至17.2,但未优于伊马替尼联合化疗(65.5% vs 59.1%,p=0.27)。
- 最常见的3-5级不良事件为发热性中性粒细胞减少(n=93)和菌血症(n=21)。
- 发生9例缓解期死亡,原因为感染(n=5)、移植相关(n=2)、心脏骤停(n=1)或原因不明(n=1);无达沙替尼相关死亡。
关键数值与推荐
- 主要终点阳性条件为满足以下之一:在AIEOP-BFM 2000高危组中优于单纯化疗;或在EsPhALL 2010队列中对伊马替尼联合化疗非劣(界值-5%)或优效。
- 达沙替尼剂量为60 mg/m2口服每日一次,自诱导第15天开始。
- 高危定义为诱导1B后微小残留病≥0.05%或三个巩固块后微小残留病阳性,分配至首次完全缓解期造血干细胞移植;标准风险接受化疗联合达沙替尼2年。
临床怎么用
- 达沙替尼联合EsPhALL化疗在儿童Ph阳性急性淋巴细胞白血病中安全且有活性,3年无事件生存率与既往试验相似,尽管首次完全缓解期造血干细胞移植使用有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The outcome of children with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia significantly improved with the combination of imatinib and intensive chemotherapy. We aimed to investigate the efficacy of dasatinib, a second-generation ABL-class inhibitor, with intensive chemotherapy in children with newly diagnosed Ph-positive acute lymphoblastic leukaemia. METHODS: CA180-372/COG AALL1122 was a joint Children's Oncology Group (COG) and European intergroup study of post-induction treatment of Ph-positive acute lymphoblastic leukaemia (EsPhALL) open-label, single-arm, phase 2 study. Eligible patients (aged >1 year to <18 years) with newly diagnosed Ph-positive acute lymphoblastic leukaemia and performance status of at least 60% received EsPhALL chemotherapy plus dasatinib 60 mg/m2 orally once daily from day 15 of induction. Patients with minimal residual disease of at least 0·05% after induction 1B or who were positive for minimal residual disease after the three consolidation blocks were classified as high risk and allocated to receive haematopoietic stem-cell transplantation (HSCT) in first complete remission. The remaining patients were considered standard risk and received chemotherapy plus dasatinib for 2 years. The primary endpoint was the 3-year event-free survival of dasatinib plus chemotherapy compared with external historical controls. The trial was considered positive if one of the following conditions was met: superiority over chemotherapy alone in the AIEOP-BFM 2000 high-risk group; or non-inferiority (with a margin of -5%) or superiority to imatinib plus chemotherapy in the EsPhALL 2010 cohort. All participants who received at least one dose of dasatinib were included in the safety and efficacy analyses. This trial was registered with ClinicalTrials.gov, NCT01460160, and recruitment is closed. FINDINGS: Between March 13, 2012, and May 27, 2014, 109 patients were enrolled at 69 sites (including 51 COG sites in the USA, Canada, and Australia, and 18 EsPhALL sites in Italy and the UK). Three patients were ineligible and did not receive dasatinib. 106 patients were treated and included in analyses (49 [46%] female and 57 [54%] male; 85 [80%] White, 13 [12%] Black or African American, five [5%] Asian, and three [3%] other races; 24 [23%] Hispanic or Latino ethnicity). All 106 treated patients reached complete remission; 87 (82%) were classified as standard risk and 19 (18%) met HSCT criteria and were classified as high risk, but only 15 (14%) received HSCT in first complete remission. The 3-year event-free survival of dasatinib plus chemotherapy was superior to chemotherapy alone (65·5% [90% Clopper-Pearson CI 57·7 to 73·7] vs 49·2% [38·0 to 60·4]; p=0·032), and was non-inferior to imatinib plus chemotherapy (59·1% [51·8 to 66·2], 90% CI of the treatment difference: -3·3 to 17·2), but not superior to imatinib plus chemotherapy (65·5% vs 59·1%; p=0·27). The most frequent grade 3-5 adverse events were febrile neutropenia (n=93) and bacteraemia (n=21). Nine remission deaths occurred, which were due to infections (n=5), transplantation-related (n=2), due to cardiac arrest (n=1), or had an unknown cause (n=1). No dasatinib-related deaths occurred. INTERPRETATION: Dasatinib plus EsPhALL chemotherapy is safe and active in paediatric Ph-positive acute lymphoblastic leukaemia. 3-year event-free survival was similar to that of previous Ph-positive acute lymphoblastic leukaemia trials despite the limited use of HSCT in first complete remission. FUNDING: Bristol Myers Squibb.
引用
- Hunger SP, Tran TH, Saha V, et al. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023. PMID: 37407142. doi:10.1016/S2352-3026(23)00088-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。